"instanceType","id","uuid:ID","rationale","versionIdentifier"
"StudyVersion","StudyVersion_1","0baa5786-dcbc-4c30-8f6f-c9a52a8a432f","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2"
